Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?

被引:0
|
作者
Erden, A. [1 ]
Batu, E. D. [2 ]
Sari, A. [1 ]
Sonmez, H. E. [2 ]
Armagan, B. [1 ]
Demir, S. [2 ]
Firat, E. [3 ]
Bilginer, Y. [2 ]
Bilgen, S. A. [1 ]
Karadag, O. [1 ]
Kalyoncu, U. [1 ]
Kiraz, S. [1 ]
Ertenli, I. [1 ]
Ozen, S. [2 ]
Akdogan, A. [1 ]
机构
[1] Hacettepe Univ, Div Rheumatol, Dept Internal Med, Fac Med, Ankara, Turkey
[2] Hacettepe Univ, Div Rheumatol, Dept Paediat, Fac Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Dept Internal Med, Fac Med, Ankara, Turkey
关键词
familial Mediterranean fever; colchicine resistance; colchicine unresponsiveness; RECOMMENDATIONS; ASSOCIATION; MANAGEMENT; DIAGNOSIS; ANAKINRA; CRITERIA; CHILDREN; SCORE; FMF;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Colchicine is the main therapy for familial Mediterranean fever (FMF); however, 5-10% of patients are colchicine-resistant. There is no standard and validated definition for colchicine resistance. We aimed to compare the existing definitions for colchicine resistance in both adult and paediatric FMF patients to find out the best definition to determine colchicine-resistant patients. Methods. 385 FMF patients were evaluated and patients receiving antiinterleukin-1 treatment were included. The anti-IL-1 therapy had been initiated by the experts in the past based on their experience. Eleven different definitions (found out after PubMed search for colchicine resistance in FMF) were applied to all patients. Results were re-analysed after excluding the patients who had no clinical attacks but persistently high acute phase reactants (APRs) and/or amyloidosis. Results. Sixty patients (40 adults/20 children) who had been using anti-IL-1 therapy were included into this study as colchicine-resistant patients. The highest percentage of patients fulfilled definition 5 (93.3%). Definition 9 had the poorest performance (26%). Significantly, a higher percentage of adult patients met definitions 4 and 6 than paediatric patients (87.5% vs. 50%, p= O. O02; 75% vs. 40%, p= O. O08, respectively). After excluding patients without clinical attacks, the highest percentage of patients fulfilled definition 2 (94.4%). We combined the attack frequency (> 1 typical episode/3 months) in definition 2 and presence of amyloidosis/APR increase (increase in ! 2/3 APRs) in definition 5 to create a new definition which was met by 59 (98.3%) colchicine-resistantF MF patients. Conclusion. Definition of colchicine resistance is still controversial. Definitions with both clinical and laboratory criteria were met by a higher percentage of resistant patients than those without laboratory criteria. However, the proper definitions for the attack-free period and persistence of APRs are still lacking.
引用
收藏
页码:S97 / S102
页数:6
相关论文
共 50 条
  • [1] Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments
    Ozen, Seza
    Kone-Paut, Isabelle
    Gul, Ahmet
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (01) : 115 - 120
  • [2] Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
    Omma, Ahmet
    Armagan, Berkan
    Guven, Serdar Can
    Sandikci, Sevinc Can
    Colak, Seda
    Yucel, Cigdem
    Kucuksahin, Orhan
    Erden, Abdulsamet
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [3] PREDICT-crFMF score: A novel model for predicting colchicine resistance in children with familial Mediterranean fever
    Ayaz, Nuray Aktay
    Demirkan, Fatma Gul
    Coskuner, Taner
    Demir, Ferhat
    Tanatar, Ayse
    cakan, Mustafa
    Karadag, Serife Gul
    Yener, Gulcin Otar
    Ozturk, Kubra
    Baglan, Esra
    cakmak, Figen
    caglayan, Senguel
    Ozdel, Semanur
    Ulu, Kadir
    Sozeri, Betul
    Sonmez, Hafize Emine
    MODERN RHEUMATOLOGY, 2023, 34 (01) : 220 - 225
  • [4] A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever
    Corsia, Alice
    Georgin-Lavialle, Sophie
    Hentgen, Veronique
    Hachulla, Eric
    Grateau, Gilles
    Faye, Albert
    Quartier, Pierre
    Rossi-Semerano, Linda
    Kone-Paut, Isabelle
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [5] Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
    Berdeli, Afig
    Senol, Ozgur
    Talay, Gamze
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2019, 6 (02) : 85 - 88
  • [6] Early predictors of colchicine resistance in familial Mediterranean fever
    Mosa, Doaa Mosad
    Shokry, Doaa
    Ahmed, Dina B.
    Sobh, Ali
    MODERN RHEUMATOLOGY, 2023, 33 (04) : 830 - 835
  • [7] Severity scores, damage indices, and the concept of the colchicine-resistant patient in familial Mediterranean fever
    Er, Ozan
    Akay, Helin
    Ozgozen, Mehmet Emre
    Gulhan, Didem
    Ugurlu, Serdal
    MODERN RHEUMATOLOGY, 2024, : 7 - 16
  • [8] Diagnostic validity of colchicine in patients with Familial Mediterranean fever
    Ozaltin, Fatih
    Bilginer, Yelda
    Gulhan, Bora
    Bajin, Inci
    Erdogan, Ozlem
    Hayran, Mutlu
    Yilmaz, Engin
    Ozen, Seza
    CLINICAL RHEUMATOLOGY, 2014, 33 (07) : 969 - 974
  • [9] Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach
    Ozen, Seza
    Sag, Erdal
    Ben-Chetrit, Eldad
    Gattorno, Marco
    Gul, Ahmet
    Hashkes, Philip J.
    Kone-Paut, Isabelle
    Lachmann, Helen J.
    Tsitsami, Elena
    Twilt, Marinka
    de Benedetti, Fabrizio
    Kuemmerle-Deschner, Jasmin B.
    RHEUMATOLOGY, 2021, 60 (08) : 3799 - 3808
  • [10] Non-response to colchicine in familial Mediterranean fever should be identified accurately
    Melikoglu, Meltem A.
    Senel, Kazim
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (12) : 2118 - 2121